RE: GF20 Aug 2020 11:43
It is the Board's expectation that the net proceeds from the Capital Raise, in addition to existing cash resources and anticipated tax credits, will be used to:
· strengthen the Company's balance sheet to support potential partnering discussions for the Company's antibody technology;
· initiate clinical trials for Modi-1 Phase 1/2 and SCIB1 Phase 2; and
· continue initial COVID-19 vaccine development until non-dilutive funding or third-party partnering transaction.
I would estimate over the next 6 months
Modi2 Mouse data will also come available ...........
BioNtech and TCR ... Its not going away ...... TCR is getting a lots of interest
Licensee: Roche (Genentech)
Licensor: Adaptive Biotech
Deal size: $2 billion
Upfront: $300 million
Assets: T cell receptor-based therapies for solid tumors
Roche’s third of four licensing deals on our 2019 list was a tie-up with Adaptive Biotech focusing on T cell receptor (TCR) therapies, a hot area of cell therapy development thanks to their potential to tackle solid tumors.
The deal promises Seattle-based Adaptive more than $2 billion in milestone payments if all goes according to plan but is remarkable for a sizable upfront fee of $300 million for access to the biotech’s TCR-hunting platform.
Adaptive’s TruTCR technology seeks out TCRs that can effectively recognize and target specific cancer neoantigens—antigens that are found in tumor cells but not normally in healthy cells—that are unique to each cancer patient.
Akin to chimeric antigen receptor T-cell (CAR-T) therapy, TCR therapy is based on giving patients immune cells that have been modified so they attack cancer cells. CAR-Ts have revolutionized the treatment of some blood cancers but haven’t made the same headway in solid tumors, and Roche’s Genentech unit is betting that Adaptive’s TCRs can fill that void.
Out of around 3,000 naturally occurring TCRs already identified through TruTCR screening are around 600 which are thought to have potential as therapeutic targets in cancer as well as autoimmune diseases, according to the biotech.
Using the TCRs, Genentech will engineer and manufacture a personalized cellular medicine to deliver to each patient. It has responsibility for clinical development, seeking regulatory approvals and commercialization of any therapies that make it through to market.
The partners expect the first cell therapy from the alliance to be ready for an application to start clinical testing before the end of the year.
The potential of TCR therapies has sparked a series of licensing deals in the last couple of years, most recently GlaxoSmithKline’s $600 million agreement with Immatics against two solid tumor targets.
Other recent examples include an Astellas link-up with Adaptimmune—worth up to $900 million—and a licensing deal with Gritstone Oncology signed by Regeneron and Bluebird bio, as well as alliances between Bluebird and Medigene and Gilead’s Kite subsidiary and HiFiBi
Sign In
Follow the stocks
